AI assistant
Revenio Group Oyj — Director's Dealing 2017
May 31, 2017
3236_rns_2017-05-31_b72aa34f-e01c-4e39-b9c8-4425ba0a422b.html
Director's Dealing
Open in viewerOpens in your device viewer
Revenio Group Corporation: Managers' transactions
Revenio Group Corporation: Managers' transactions
Revenio Group Corporation, Managers' transactions, May 31, 2017 at 15:30
Revenio Group Corporation: Managers' transactions
Person subject to the notification requirement
Name: Kukkonen, Ari
Position: Other senior manager
Initial Notification
Reference number: 743700I27E0FWSXLKK04_20170524134242_2
Issuer
Name: Revenio Group Oyj
LEI: 743700I27E0FWSXLKK04
Transaction details
Transaction date: 2017-05-30
Nature of the Acceptance of a Stock Option
transaction:
Further details:
Linked to stock option programme
Instrument: Financial Instrument Linked to a Share or a Debt
Instrument
ISIN: FI4000261037
Volume: 5000
Unit price:
Aggregated transactions
Volume: 5000
Volume weighted average
price:
For further information, please contact: Robin Pulkkinen, CFO, +358 50 5059932
Distribution:
Nasdaq Helsinki
www.revenio.fi
The Revenio Group in brief
Revenio is a Finnish, globally operating health technology corporation whose
worldwide success is based on a strongly patented intraocular pressure
measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio
Research Oy and Oscare Medical Oy, in which Revenio holds a 53.5% interest. The
common denominators of Revenio's business operations include screening, follow-
up and the global need to make cost savings through preventive health care.
Revenio seeks vigorous growth in health technology. Revenio aims to develop even
more efficient and easily adopted methods for the early-stage detection of
diseases with significance for public health. The focus of Revenio's screening
technology is on the early detection of glaucoma, osteoporosis, skin cancer and
asthma, and the monitoring of these during the treatment process.
In 2016, Revenio Group's net sales totaled MEUR 23.4, with its operating profit
for continuing operations standing at 30.1%. Revenio Group Corporation is listed
on Nasdaq Helsinki.
[]